Hepatic oligometastases treated with stereotactic body radiation therapy: Updated 10-year analysis of the Indiana University experience.

Authors

null

Ben Goodman

Indiana University, Indianapolis, IN

Ben Goodman , Higinia Rosa Cardenes , Mary A. Maluccio , Paul R. Helft

Organizations

Indiana University, Indianapolis, IN, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Department of General Surgery, Indianapolis, IN

Research Funding

No funding sources reported

Background: Stereotactic body radiation therapy (SBRT) is a non-invasive, effective technique in the treatment of a limited number of liver metastases from solid tumors. We present the 10 year update of our single institution SBRT experience outcomes and toxicity. This is thought to be the largest single institution experience present in the literature. Methods: We treated 81 patients 89 different times, for a total of 106 lesions. Inclusion criteria were patients with 1-3 liver metastases without evidence of extra-hepatic progression, and at least 700 cc of liver (minus the GTV) receiving less than 1500 cGy. The majority of patients had colorectal primary cancers. Other diagnoses included: Non-colorectal GI, breast, ovarian, NSCLC, and others. Among the lesions treated the majority received prior chemotherapy. Results: The median overall survival was 31 months. Kaplan Meier survival estimates at 12, 24, 36, and 48 months were 85%, 61%, 34%, and 18%. The local control rate was 94% with Kaplan Meier estimates at 12, 24, 36, and 48 months being 95%, 90%, 90% and 90%. The observed toxicities noted among the 106 treatments included mostly CTC grade 1-2 toxicity with only two grade 4 and one grade 5 toxicity. There was no difference in the toxicity based on the primary site. The majority of patients had grade 1 to 2 non-hepatic GI toxicity, grade 1-2 fatigue or grade 1-2 chest wall pain. The most severe toxicity noted was 1 patient with grade 5 hepatic toxicity and 2 patients with grade 4 hepatic toxicity. In addition, two patients developed grade 1 pleural effusions thought to be secondary to treatment. Parameters affecting toxicity were evaluated based on grade 4-5 hepatic toxicity. Generalized estimating equation models were fit to test for an association between each categorical factor and grade 4-5 hepatic toxicity. Linear mixed models were used to test for an association between each continuous factor and grade 4-5 hepatic toxicity. The only patient with grade 5 toxicity was treated three different times to a total of four lesions. Conclusions: Stereotactic body radiation therapy is a safe and effective treatment for patients with 1-3 liver metastases with a limited toxicity profile.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3583)

DOI

10.1200/jco.2014.32.15_suppl.3583

Abstract #

3583

Poster Bd #

46

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Gastrointestinal Cancers Symposium

Central hepatobiliary toxicity in patients treated with stereotactic body radiotherapy (SBRT) for liver malignancies.

First Author: Nitika Thawani

First Author: Jonathan W. Lischalk

First Author: Young Suk Suk Kwon